9-24-20 - JAK2 The Future_ Updates in the Biology and Treatment of Myeloproliferative Neoplasms

The value of novel JAK2 and CALR-targeted therapies in MPNsПодробнее

JAK2 V617F Mutations (Myeloproliferative neoplasms (MPNs)): A blood disorderПодробнее

POLYCYTHEMIA VERA Etiology Molecular pathogenesis of JAK2V617F mutation. JAK2 kinaseПодробнее

JAK2 Inhibition in the Treatment of MyelofibrosisПодробнее

MPN disease biology: JAK2.V617F causes lymphopenia by blocking lymphopoiesisПодробнее

Understanding aberrant signaling pathways to prevent resistance to JAK2 inhibitors in MPNsПодробнее

Shining a Light on MPNs: Myeloproliferative Neoplasms with Dr. Noah MerinПодробнее

What if we could adapt cancer treatments as tumors mutate and change?Подробнее

Living Well With MPNs What You Should Know About Genetic MutationsПодробнее

Beyond JAK2 Inhibitors: New targets and new agentsПодробнее

Biology and Therapy of Eosinophilic MPNsПодробнее

Mathematical modeling of blood cancer and premalignancyПодробнее

Dr. Michaelis Discusses the JAK2 Mutation in MPNsПодробнее

Effects of tamoxifen on the mutant allele burden in MPNsПодробнее

A study of dizygotic twins with JAK2-positive MPNsПодробнее

Molecular analysis in the diagnosis and prognosis of haematological malignanciesПодробнее

Rationale for JAK Inhibition in PVПодробнее

Debate: Survival benefit of JAK2 inhibitors in MyelofibrosisПодробнее

Beyond JAK2 Inhibitors: New Targets and New AgentsПодробнее